Holen Sie sich die Stockscreener-App
20.11
3.62%
-0.90
Schlusskurs vom Vortag:
$21.01
Offen:
$20.11
24-Stunden-Volumen:
5,592
Relative Volume:
1.36
Marktkapitalisierung:
$1.88B
Einnahmen:
$80.00M
Nettoeinkommen (Verlust:
$-172.98M
KGV:
-10.36
EPS:
-1.9419
Netto-Cashflow:
$-178.54M
1W Leistung:
+6.64%
1M Leistung:
-15.45%
6M Leistung:
-36.96%
1J Leistung:
-23.53%
1-Tages-Spanne:
$20.11
$20.70
1-Wochen-Bereich:
$19.29
$22.58
52-Wochen-Spanne:
$18.56
$48.45
Ascentage Pharma Group International Adr Stock (AAPG) Company Profile
Firmenname
Ascentage Pharma Group International Adr
Sektor
Branche
Telefon
-
Adresse
-
Compare AAPG vs VRTX, REGN, ARGX, ALNY, RVMD
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
AAPG
Ascentage Pharma Group International Adr
|
20.13 | 1.96B | 80.00M | -172.98M | -178.54M | -1.9419 |
VRTX
Vertex Pharmaceuticals Inc
|
436.52 | 110.28B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
634.88 | 66.98B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
806.13 | 50.15B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
294.74 | 39.71B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
154.40 | 32.22B | 742.00K | -1.37B | -1.07B | -7.0731 |
Ascentage Pharma Group International Adr Stock (AAPG) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-04-24 | Eingeleitet | Deutsche Bank | Buy |
| 2026-03-12 | Fortgesetzt | BTIG Research | Buy |
| 2026-01-13 | Eingeleitet | Rodman & Renshaw | Buy |
| 2025-12-04 | Eingeleitet | Oppenheimer | Outperform |
| 2025-11-24 | Eingeleitet | Truist | Buy |
| 2025-11-10 | Eingeleitet | BTIG Research | Buy |
| 2025-11-05 | Eingeleitet | Piper Sandler | Overweight |
| 2025-03-27 | Eingeleitet | JP Morgan | Overweight |
Alle ansehen
Ascentage Pharma Group International Adr Aktie (AAPG) Neueste Nachrichten
AAPG Stock Price, Quote & Chart | ASCENTAGE PHARMA GR-ADR (NASDAQ:AAPG) - ChartMill
Analysts Offer Insights on Healthcare Companies: IQVIA Holdings (IQV), BeOne Medicines (ONC) and Nektar Therapeutics (NKTR) - The Globe and Mail
Ascentage Pharma: Buy Rating Reiterated on Advancing CML/ALL Pipeline and DCF-Supported Unchanged $48 Price Target - TipRanks
Analysts Are Bullish on These Healthcare Stocks: SI-Bone (SIBN), Perspective Therapeutics (CATX) - The Globe and Mail
Ascentage Pharma to Present 17 Hematology Clinical Updates at June 2026 EHA Congress - TipRanks
Analysts Offer Insights on Healthcare Companies: Health Catalyst (HCAT), Liquidia Technologies (LQDA) and Bicara Therapeutics Inc. (BCAX) - The Globe and Mail
Ascentage Pharma to Present 17 Clinical Advances at 2026 European Hematology Association Congress - ChartMill
Ascentage Pharma to Highlight Oncology Portfolio at May–June 2026 Investor Conferences - TipRanks
Analysts Offer Insights on Healthcare Companies: Joint (JYNT), Regeneron (REGN) and Collegium Pharmaceutical (COLL) - The Globe and Mail
AAPG: Ascentage Pharma Group InternationalUnsponsored ADRInteractive Chart - Zacks Investment Research
Analysts Are Bullish on Top Healthcare Stocks: CG Oncology, Inc. (CGON), Evolus (EOLS) - The Globe and Mail
Ascentage Pharma Group International (NASDAQ:AAPG) Shares Gap DownTime to Sell? - MarketBeat
Analysts’ Opinions Are Mixed on These Healthcare Stocks: Opus Genetics (IRD), NeoGenomics (NEO) and Teladoc (TDOC) - The Globe and Mail
Ascentage Pharma Group InternationalUnsponsored ADR (NASDAQ:AAPG) Short Interest Down 51.1% in April - MarketBeat
Analysts’ Top Healthcare Picks: AbbVie (ABBV), Regeneron (REGN) - The Globe and Mail
Ascentage Pharma Group International (NASDAQ:AAPG) Sees Large Volume IncreaseHere's Why - MarketBeat
Ascentage Pharma Group International (NASDAQ:AAPG) Shares Down 8.4%What's Next? - MarketBeat
Ascentage Pharma to Present Data from Multiple Trials, Including Three Rapid Oral Presentations, at ASCO 2026 - GlobeNewswire Inc.
Analysts Offer Insights on Healthcare Companies: Monopar Therapeutics Inc (MNPR) and Agios Pharma (AGIO) - The Globe and Mail
Ascentage (AAPG) Stock: Support and Resistance (Momentum Fading) 2026-04-16Momentum Investing - Xã Thanh Hà
Ascentage Pharma Group International (NASDAQ:AAPG) Shares Gap UpShould You Buy? - MarketBeat
Applied Digital, Simply Good Foods And Other Big Stocks Moving Lower In Thursday's Pre-Market Session - Sahm
Analysts Are Bullish on These Healthcare Stocks: GE Healthcare Technologies Inc (GEHC), Nuvation Bio (NUVB) - The Globe and Mail
Ascentage Pharma Group International (NASDAQ:AAPG) Upgraded at China Intl Cap - Defense World
Ascentage Pharma Group International (NASDAQ:AAPG) Trading Up 12%Should You Buy? - MarketBeat
Wall Street Analysts Are Bullish on Top Healthcare Picks - The Globe and Mail
Why nCino Shares Are Trading Higher By 18%; Here Are 20 Stocks Moving Premarket - Sahm
Truist Financial Remains a Buy on Ascentage Pharma Group International Unsponsored ADR (AAPG) - The Globe and Mail
BTIG Remains a Buy on Ascentage Pharma Group International Unsponsored ADR (AAPG) - The Globe and Mail
Earnings Scheduled For March 25, 2026 - Sahm
Ascentage Pharma Group International (NASDAQ:AAPG) Shares Up 20.3%Should You Buy? - marketbeat.com
Short Interest in Ascentage Pharma Group InternationalUnsponsored ADR (NASDAQ:AAPG) Increases By 546.9% - MarketBeat
Ascentage Pharma Group International (NASDAQ:AAPG) Stock Price Down 7.7%Here's Why - MarketBeat
Ascentage Pharma to Present Data From Four Preclinical Studies In Its Innovative Pipeline at American Association of Cancer Research (AACR) Annual Meeting 2026 - Sahm
Ascentage Pharma Sets March 25 Board Meeting on 2025 Results and Potential Final Dividend - TipRanks
Ascentage Pharma Sets March 25, 2026 Date to Unveil 2025 Unaudited Results and Business Update - The Globe and Mail
Finanzdaten der Ascentage Pharma Group International Adr-Aktie (AAPG)
Umsatz
Nettogewinn
Free Cashflow
ENV
Ascentage Pharma Group International Adr-Aktie (AAPG) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Zhai Yifan | Chief Medical Officer |
May 21 '26 |
Option Exercise |
0.00 |
92,746 |
0 |
405,280 |
| Yang Dajun | Chairman and CEO |
May 21 '26 |
Option Exercise |
0.00 |
92,746 |
0 |
405,280 |
| Yang Dajun | Chairman and CEO |
May 21 '26 |
Option Exercise |
0.00 |
95,575 |
0 |
1,193,569 |
2.25%
0.46%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):